Evaxion Biotech A/S (NASDAQ:EVAX) Q4 2023 Earnings Call Transcript April 2, 2024
Evaxion Biotech A/S isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).
Christian Kanstrup: Hello, everyone, and a very warm welcome to this Evaxion Business Update Conference call on the back of our Full Year 2023 Results. I’m Christian Kanstrup. I’m the CEO of Evaxion. With me today, I have Birgitte Rono, our Chief Scientific Officer. I have...
